Apr 29, 2020
AbbVie Inc. - Rule 2.10 Announcement - Relevant Securities in Issue
Apr 28, 2020
Announcement relating to the voluntary delisting of Allergan Notes
Apr 27, 2020
Graft Versus Host Disease (GvHD) Pipeline Guide, H1 2020
Apr 27, 2020
AbbVie Announces Extension of Expiration Date for Exchange Offers for Allergan Notes
Apr 22, 2020
Influenzavirus B Infections - Pipeline Review, H1 2020
Apr 15, 2020
Visiongain Publishes Biopharmaceuticals Contract Manufacturing Market Report 2020-2030
Apr 15, 2020
AbbVie Inc. - Rule 2.10 Announcement - Relevant Securities in Issue
Apr 14, 2020
Worldwide Licensing Partnering Deals in Pharma, Biotech & Diagnostics, 2014-2020
Apr 09, 2020
Global Pharma, Biotech & Diagnostics Co-promotion & Co-marketing Partnering Terms & Agreements Report, 2014-2020
Apr 09, 2020
Worldwide Autoimmune Partnering Deals Review 2014-2020: Gain Access Autoimmune Deal Headline, Upfront, Milestone and Royalty Data
Apr 09, 2020
Collaborative R&D Partnering Deals in Pharma, Biotech & Diagnostics 2014-2020: A Comprehensive Listing of 5,000+ Collaborative R&D Deals
Apr 09, 2020
Royalty Rates in Worldwide Pharma & Biotech Dealmaking 2010-2020: Case Studies, Trends, Leading Deals and More
Apr 09, 2020
Co-development Partnering Terms & Agreements in Global Pharma, Biotech & Diagnostics Sectors 2014-2020: Key Trends, Players and Financials
Apr 09, 2020
Global Dermatology Partnering Terms & Agreements 2014-2020: Benchmark the Key Deal Terms Companies Have Agreed in Previous Deals
Apr 08, 2020
AbbVie Invites Students with Cystic Fibrosis to Apply for the AbbVie CF Scholarship for the 2020-2021 Academic School Year
Apr 08, 2020
Roche Tops the Pharmaceutical Innovation Index for the First Time; AstraZeneca Ranks 1st for Its Pipeline
Apr 02, 2020
AbbVie to Host First-Quarter 2020 Earnings Conference Call
Apr 02, 2020
AbbVie Inc. - Form 8.1 - Dealings By Offerors, Offerees Or Parties Acting In Concert With Them For Themselves Or For Discretionary Clients
Apr 02, 2020
Visiongain Launches Report Examining the Potential in the $11bn Pharma Contract Sales Market
Apr 01, 2020
AbbVie Inc. - Rule 2.10 Announcement - Relevant Securities in Issue